How should a patient with diarrhoea‑predominant irritable bowel syndrome be treated?

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Start with loperamide 2–4 mg up to four times daily as first-line pharmacologic therapy for IBS-D, titrating carefully to avoid constipation, bloating, or abdominal pain. 1

First-Line Lifestyle and Dietary Interventions

• Recommend regular aerobic exercise to all IBS-D patients as foundational therapy, as this independently improves global symptom severity and should be instituted before escalating to second-line medications. 1, 2

• Provide dietary counseling to identify and reduce excessive intake of indigestible carbohydrates, lactose (if consuming >280 mL milk/day), fructose, sorbitol, caffeine, and alcohol, as these worsen diarrhea-predominant symptoms. 1, 2

• Initiate soluble fiber (psyllium/ispaghula) at 3–4 g daily and titrate upward gradually to improve global IBS symptoms and abdominal pain while minimizing bloating; this is effective across all IBS subtypes including IBS-D. 1, 2

• Avoid insoluble fiber such as wheat bran, which consistently aggravates bloating, abdominal pain, and overall symptom burden in all IBS subtypes. 1, 2

• Offer a 12-week trial of probiotics for global symptoms and abdominal pain; discontinue if no improvement is observed, noting that no specific strain has demonstrated superiority. 1, 2

• If symptoms persist after 4–6 weeks of first-line measures, refer to a trained dietitian for a supervised low-FODMAP diet delivered in three phases: restriction (4–6 weeks), systematic reintroduction, and personalized long-term maintenance. 1, 2, 3

First-Line Pharmacologic Therapy for Diarrhea

• Prescribe loperamide 2–4 mg up to four times daily (regular dosing or prophylactically before outings) to reduce stool frequency, urgency, and fecal soiling; dose titration is required to avoid constipation, bloating, or abdominal pain. 1, 2

• Loperamide improves stool consistency but does not affect overall symptom burden or abdominal pain, so additional therapies targeting pain are often necessary. 1, 2

First-Line Pharmacologic Therapy for Abdominal Pain

• Prescribe antispasmodics with anticholinergic properties (dicyclomine) taken before meals as first-line therapy for meal-related abdominal pain; counsel patients about dry mouth, visual disturbances, and dizziness. 1, 2, 4

• Peppermint oil is an alternative antispasmodic with a more favorable side-effect profile for abdominal pain and can be used if dicyclomine is not tolerated. 1, 2, 4

Second-Line Pharmacologic Therapy for Persistent Diarrhea

• 5-HT₃ receptor antagonists (ondansetron titrated from 4 mg once daily to a maximum of 8 mg three times daily) are the most efficacious second-line drugs for IBS-D when loperamide fails after 4–6 weeks; constipation is the most common side effect. 1

• Rifaximin is an effective second-line agent for global IBS-D symptoms, though its impact on abdominal pain is limited and it is not available for this indication in many countries. 1, 5, 6, 7, 8

• Eluxadoline is an efficacious second-line drug for IBS-D, but it is contraindicated in patients with prior sphincter of Oddi problems or cholecystectomy, alcohol dependence, pancreatitis, or severe liver impairment, and lack of availability may limit its use. 1, 5, 6, 7, 8

• Do NOT prescribe alosetron due to serious safety concerns, including risk of ischemic colitis (0.2% through 3 months, 0.3% through 6 months) and complications of constipation. 1, 9, 5, 7, 8

• Screen for bile-acid malabsorption (SeHCAT scan or serum 7α-hydroxy-4-cholesten-3-one) in patients with nocturnal diarrhea or a history of cholecystectomy; if positive (SeHCAT retention <5%), treat with cholestyramine, though tolerability is poor and many patients prefer loperamide. 1, 2

Second-Line Neuromodulator Therapy for Refractory Pain

• Tricyclic antidepressants (amitriptyline) are the most effective second-line treatment for global symptoms and abdominal pain across all IBS subtypes; start at 10 mg nightly and titrate by 10 mg weekly to a target of 30–50 mg daily. 1, 2, 4, 10

• Continue effective tricyclic therapy for at least 6 months before considering discontinuation if sustained symptomatic improvement is reported. 1, 2, 4, 10

• Counsel patients about common amitriptyline adverse effects: dry mouth, visual disturbances, and dizziness. 1, 2

• Selective serotonin reuptake inhibitors (SSRIs) may be used as second-line neuromodulators when TCAs are not tolerated, although supporting evidence is weaker and pooled data from five RCTs show no significant improvement in global relief or abdominal pain in IBS-D. 1, 2

Third-Line Psychological Therapies for Refractory Symptoms

• Offer IBS-specific cognitive-behavioral therapy (CBT) and gut-directed hypnotherapy when symptoms remain refractory after at least 12 months of optimal pharmacologic management; both modalities reduce overall symptom burden. 1, 2, 10

Treatment Monitoring and Reassessment

• Assess treatment efficacy at 3 months; discontinue any therapy that does not provide meaningful benefit. 1, 2, 10

• Refer to gastroenterology when diagnostic uncertainty exists, alarm features are present (rectal bleeding, unintentional weight loss ≥5%, anemia, fever, nocturnal symptoms, family history of IBD or colorectal cancer), symptoms are severe or refractory after 12 weeks of first-line therapy, or the patient requests specialist input. 1, 2

Critical Pitfalls to Avoid

• Do NOT prescribe opioid analgesics for chronic abdominal pain in IBS-D due to high risk of dependence, complications, and potential worsening of constipation. 1, 2, 4, 10

• Do NOT prescribe alosetron due to serious safety concerns including ischemic colitis and severe complications of constipation. 1, 9

• Do NOT recommend IgG antibody-based food elimination diets, as they lack supporting evidence and may lead to unnecessary dietary restrictions. 1, 2

• Do NOT recommend gluten-free diets unless celiac disease is confirmed by serology and biopsy. 1, 2

• Explain to patients that IBS-D is a gut-brain interaction disorder with a benign, relapsing-remitting course that does not progress to cancer or inflammatory bowel disease, which reduces anxiety and improves adherence. 1, 2